Adaptive Biotechnologies (ADPT) Income from Non-Controlling Interests (2021 - 2026)
Adaptive Biotechnologies (ADPT) posted Income from Non-Controlling Interests of $18000.0 for Q1 2026, up 1900.0% sequentially from -$1000.0 in Q3 2025, and down 18.18% YoY from $22000.0 in Q1 2025.
Adaptive Biotechnologies (ADPT) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
Adaptive Biotechnologies has reported Income from Non-Controlling Interests for 6 years, with the latest figure at $18000.0 in Q1 2026.
- Quarterly Income from Non-Controlling Interests fell 18.18% year-over-year to $18000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38000.0 (up 169.09% YoY) and the FY2025 annual result came in at $42000.0, up 140.78% from the prior year.
- Income from Non-Controlling Interests improved to $18000.0 in Q1 2026 per ADPT's latest filing, from -$1000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $22000.0 in Q1 2025 and troughed at -$60000.0 in Q1 2022.
- A 5-year average of -$17125.0 and a median of -$26000.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2024 and 2025: Income from Non-Controlling Interests tumbled 2500.0% in 2024, then soared 184.62% in 2025.
- Over 5 years, Income from Non-Controlling Interests stood at -$41000.0 in 2022, then soared by 36.59% to -$26000.0 in 2023, then advanced by 3.85% to -$25000.0 in 2024, then jumped by 96.0% to -$1000.0 in 2025, then jumped by 1900.0% to $18000.0 in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $18000.0, -$1000.0, and $21000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.78 Bn | 209.71 Bn | 8.34 Bn | 5.00 Mn |
| 2 | Danaher | 139.83 Bn | 135.48 Bn | 3.61 Bn | - |
| 3 | Idexx Laboratories | 45.99 Bn | 45.79 Bn | 779.09 Mn | - |
| 4 | Agilent Technologies | 39.69 Bn | 37.88 Bn | 990.00 Mn | - |
| 5 | Iqvia Holdings | 39.31 Bn | 37.23 Bn | 1.44 Bn | 2.00 Mn |
| 6 | Natera | 38.74 Bn | 37.64 Bn | 696.04 Mn | - |
| 7 | Illumina | 29.94 Bn | 28.77 Bn | 770.00 Mn | - |
| 8 | Mettler Toledo International | 28.55 Bn | 28.50 Bn | 650.22 Mn | - |
| 9 | Quest Diagnostics | 26.18 Bn | 25.55 Bn | 1.03 Bn | 14.00 Mn |
| 10 | Adaptive Biotechnologies | 3.83 Bn | 3.61 Bn | 52.17 Mn | 18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | 21,000.00 |
| Mar 31, 2025 | 22,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Sep 30, 2024 | -26,000.00 |
| Jun 30, 2024 | -26,000.00 |
| Mar 31, 2024 | -26,000.00 |
| Dec 31, 2023 | -26,000.00 |
| Sep 30, 2023 | -26,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Mar 31, 2023 | -1,000.00 |
| Dec 31, 2022 | -41,000.00 |
| Sep 30, 2022 | -38,000.00 |
| Jun 30, 2022 | -38,000.00 |
| Mar 31, 2022 | -60,000.00 |
| Dec 31, 2021 | 76,000.00 |
| Sep 30, 2021 | -95,000.00 |